CRISPR/Cas9 somatic multiplex-mutagenesis for high-Throughput functional cancer genomics in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 45, 2015, Pages 13982-13987

  Weber, Julia ^a,b   Öllinger, Rupert ^a   Friedrich, Mathias ^c   Ehmer, Ursula ^a   Barenboim, Maxim ^a,b   Steiger, Katja ^a   Heid, Irina ^a   Mueller, Sebastian ^a   Maresch, Roman ^a,b   Engleitner, Thomas ^a,b   Gross, Nina ^a,b   Geumann, Ulf ^a,b   Fu, Beiyuan ^c   Segler, Angela ^a   Yuan, Detian ^a   Lange, Sebastian ^a   Strong, Alexander ^c   Rosa, Jorge De La ^c   Esposito, Irene ^c   Liu, Pentao ^d   Cadiñanos, Juan ^c   Vassiliou, George S ^e   Schmid, Roland M ^c   Schneider, Gönter ^a,b   Unger, Kristian ^a   Yang, Fengtang ^f   Braren, Rickmer ^c   Heikenwälder, Mathias ^g   Varela, Ignacio ^d,e   Saur, Dieter ^b   Bradley, Allan ^b,h   Rad, Roland ^a,b   more..

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f Instituto de Medicina Oncologica y Molecular de Asturias   (Spain)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h University of Cantabria   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CRISPR ASSOCIATED PROTEIN; CRISPR ASSOCIATED PROTEIN 9; CYCLIN DEPENDENT KINASE INHIBITOR 2A; GUIDE RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SINGLE GUIDE RNA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; BILE DUCT CARCINOMA; CARCINOGENESIS; CHROMOSOME; CHROMOSOME REARRANGEMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CONFERENCE PAPER; CONTROLLED STUDY; EXON; GENE TARGETING; GENETIC HETEROGENEITY; GENETIC SCREENING; GENOMICS; HIGH THROUGHPUT SEQUENCING; INVERTED REPEAT; LIVER CELL CARCINOMA; LIVER TUMOR; MOUSE; NONHUMAN; PHENOTYPE; PHYLOGENETIC TREE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOMATIC MUTATION; TUMOR GENE; TUMOR SUPPRESSOR GENE; ANIMAL; CRISPR CAS SYSTEM; DISEASE MODEL; GENETIC SELECTION; GENETICS; HIGH THROUGHPUT SCREENING; HISTOLOGY; LIVER; METABOLISM; MOLECULAR GENETICS; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PROCEDURES;

ANIMALS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; GENE TARGETING; GENOMICS; HIGH-THROUGHPUT SCREENING ASSAYS; HISTOLOGICAL TECHNIQUES; LIVER; LIVER NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; SELECTION, GENETIC;

EID: 84946771643     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1512392112     Document Type: Article

References (47)

1. Stratton MR (2011) Exploring the genomes of cancer cells: Progress and promise. Science 331(6024):1553-1558.
2. Copeland NG, Jenkins NA (2010) Harnessing transposons for cancer gene discovery. Nat Rev Cancer 10(10):696-706.
3. Rad R, et al. (2010) PiggyBac transposon mutagenesis: A tool for cancer gene discovery in mice. Science 330(6007):1104-1107.
4. Bradley A, Evans M, Kaufman MH, Robertson E (1984) Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. Nature 309(5965):255-256.
5. Doetschman T, et al. (1987) Targetted correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 330(6148):576-578.
6. van Miltenburg MH, Jonkers J (2012) Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Curr Opin Genet Dev 22(1):21-27.
7. Horvath P, Barrangou R (2010) CRISPR/Cas, the immune system of bacteria and archaea. Science 327(5962):167-170.
8. Garneau JE, et al. (2010) The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468(7320):67-71.
9. Jinek M, et al. (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337(6096):816-821.
10. Wiedenheft B, Sternberg SH, Doudna JA (2012) RNA-guided genetic silencing systems in bacteria and archaea. Nature 482(7385):331-338.
11. Cong L, et al. (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339(6121):819-823.
12. Mali P, et al. (2013) RNA-guided human genome engineering via Cas9. Science 339(6121):823-826.
13. Sander JD, Joung JK (2014) CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol 32(4):347-355.
14. Wang H, et al. (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 153(4):910-918.
15. Yin H, et al. (2014) Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol 32(6):551-553.
16. Xue W, et al. (2014) CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514(7522):380-384.
17. Platt RJ, et al. (2014) CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159(2):440-455.
18. Maddalo D, et al. (2014) In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516(7531):423-427.
19. Sánchez-Rivera FJ, et al. (2014) Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516(7531):428-431.
20. Blasco RB, et al. (2014) Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology. Cell Reports 9(4):1219-1227.
21. Yant SR, et al. (2000) Somatic integration and long-Term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 25(1):35-41.
22. Ong CK, et al. (2012) Exome sequencing of liver fluke-Associated cholangiocarcinoma. Nat Genet 44(6):690-693.
23. Jiao Y, et al. (2013) Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 45(12):1470-1473.
24. Chan-On W, et al. (2013) Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet 45(12):1474-1478.
25. Ross JS, et al. (2014) New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19(3):235-242.
26. Fujimoto A, et al. (2012) Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44(7):760-764.
27. Guichard C, et al. (2012) Integrated analysis of somatic mutations and focal copynumber changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44(6):694-698.
28. Huang J, et al. (2012) Exome sequencing of hepatitis B virus-Associated hepatocellular carcinoma. Nat Genet 44(10):1117-1121.
29. Schulze K, et al. (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47(5):505-511.
30. Delire B, Stärkel P (2015) The Ras/MAPK pathway and hepatocarcinoma: Pathogenesis and therapeutic implications. Eur J Clin Invest 45(6):609-623.
31. Sia D, et al. (2013) Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144(4):829-840.
32. Horie Y, et al. (2004) Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113(12):1774-1783.
33. Simbolo M, et al. (2014) Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget 5(9):2839-2852.
34. Boyault S, et al. (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45(1):42-52.
35. Xu X, et al. (2006) Induction of intrahepatic cholangiocellular carcinoma by liverspecific disruption of Smad4 and Pten in mice. J Clin Invest 116(7):1843-1852.
36. O'Dell MR, et al. (2012) Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res 72(6):1557-1567.
37. Wang T, Wei JJ, Sabatini DM, Lander ES (2014) Genetic screens in human cells using the CRISPR-Cas9 system. Science 343(6166):80-84.
38. Shalem O, et al. (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343(6166):84-87.
39. Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera MdelC, Yusa K (2014) Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol 32(3):267-273.
40. Chen S, et al. (2015) Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160(6):1246-1260.
41. Wang P, et al. (2013) Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 32(25):3091-3100.
42. Dang L, et al. (2010) Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465(7300):966.
43. Ward PS, et al. (2010) The common feature of leukemia-Associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17(3):225-234.
44. Guilhamon P, et al. (2013) Meta-Analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2. Nat Commun 4:2166.
45. Figueroa ME, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18(6):553-567.
46. Zender L, et al. (2008) An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135(5):852-864.
47. Xue W, et al. (2012) A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci USA 109(21):8212-8217.